We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC's StarGuide GX holds CE Mark approval in Europe, but FDA clearance remains pending in the United States.
GE HealthCare (GEHC - Free Report) recently announced five new global clinical collaborations to evaluate its next-generation StarGuide GX digital SPECT/CT system, aimed at advancing quantitative imaging, dynamic imaging and emerging theranostics applications. The program involves leading healthcare institutions across the United States, Europe, Israel and China, with clinical insights expected to guide the future development of the company’s nuclear medicine imaging platform.
The initiative highlights GEHC’s continued focus on innovation in molecular imaging and precision medicine, particularly as theranostics gains traction in cancer diagnosis and treatment. Collaborations with established medical institutions could help strengthen clinical validation, support broader adoption of advanced imaging technologies and reinforce the company’s competitive position in nuclear medicine. However, the program’s financial contribution will depend on the pace of commercialization, regulatory clearances and eventual customer demand for StarGuide GX.
GEHC Stock Trend Following the News
Following the announcement on Oct. 20, GEHC stock has traded flat till yesterday’s closing. Year to date, shares of the company have lost 15.9% compared with the industry’s 20% decline and the S&P 500’s 12.7% rise.
The global clinical evaluation program could support GEHC’s long-term growth by strengthening the clinical evidence behind its advanced molecular imaging portfolio and expanding the potential applications of the StarGuide GX platform. Feedback from leading healthcare institutions may help refine the system’s quantitative imaging capabilities, improve clinical workflows and support the development of next-generation nuclear medicine solutions. These advances could enhance GEHC’s competitive positioning in theranostics and precision oncology, where demand for technologies that help guide treatment decisions and monitor therapeutic response is growing.
GEHC currently has a market capitalization of $108.02 billion.
Image Source: Zacks Investment Research
More on the News
GEHC StarGuide GX is a next-generation digital 4D single-photon emission computed tomography/computed tomography (SPECT/CT) system designed to advance quantitative and dynamic imaging in nuclear medicine. The platform uses dual-sided cadmium zinc telluride (dsCZT) detector technology to support high-sensitivity, high-resolution imaging and quantitative assessment. Its detector configuration allows the detectors to move closer to the patient during imaging, while the patented dual-collimator design is intended to eliminate manual external collimator exchanges and streamline workflows. These features are designed to support imaging efficiency while improving the precision of nuclear medicine assessments.
The system is engineered to accommodate radionuclides across a broad energy range, with research evaluations potentially extending to radionuclides associated with emerging alpha-emitter applications, including Actinium-225. This could help expand its potential role in theranostics, which combines diagnostic imaging with targeted treatment. In addition, NVIDIA RTX accelerated computing supports image reconstruction, while the Low-Medium Energy collimator is designed to deliver up to 2.67 times system volume sensitivity. Together, these capabilities could help clinicians obtain more detailed imaging data and support the evolving requirements of personalized medicine and advanced oncology care.
The five participating institutions will evaluate the platform according to their clinical and research priorities. Hadassah Medical Center will assess its advanced quantitative capabilities following a recent field upgrade, while Mayo Clinic will focus on quantitative and dynamic imaging applications. Oncopole Claudius Regaud in France will evaluate the system in routine oncology imaging and clinical research, Peking University First Hospital will explore novel tracer research and preclinical applications, and Rambam Health Care Campus will assess imaging workflows across a broad range of nuclear medicine applications and tracers.
The program builds on GEHC’s collaboration with University Hospital Essen in Germany, which opened a nuclear medicine center in June 2026 featuring the first installation of StarGuide GX SPECT/CT. The participating institutions have collectively conducted more than 1,000 patient scans.
StarGuide GX received CE Mark in November 2025 and is available for sale in select European Union member states. However, FDA 510(k) clearance remains pending, and the system is not currently available for sale in the United States.
Industry Prospects Favoring the Market
According to data provided by Mordor Intelligence, the radiopharmaceutical theranostics market size is expected to grow from $2.66 billion in 2026 to $4.46 billion by 2031 at 10.89% CAGR.
The radiopharmaceutical theranostics market is driven by rising cancer incidence, growing adoption of targeted radioligand therapies and increasing demand for precision oncology. Advances in radiopharmaceuticals, expanding clinical applications, favorable regulatory developments and investments in isotope production and nuclear medicine infrastructure are expected to support long-term market growth.
Other News
GEHC recently announced that the MINItrace Magni cyclotron has received CE Mark certification, advancing its efforts to expand local production of radioisotopes used in positron emission tomography (“PET”) imaging. The company also expanded the PETtrace Solid Target Platform to support Copper-64 production, broadening its capabilities beyond Gallium-68 and Zirconium-89.
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
GEHC Expands Theranostics Imaging With 5 Global Collaborations
Key Takeaways
GE HealthCare (GEHC - Free Report) recently announced five new global clinical collaborations to evaluate its next-generation StarGuide GX digital SPECT/CT system, aimed at advancing quantitative imaging, dynamic imaging and emerging theranostics applications. The program involves leading healthcare institutions across the United States, Europe, Israel and China, with clinical insights expected to guide the future development of the company’s nuclear medicine imaging platform.
The initiative highlights GEHC’s continued focus on innovation in molecular imaging and precision medicine, particularly as theranostics gains traction in cancer diagnosis and treatment. Collaborations with established medical institutions could help strengthen clinical validation, support broader adoption of advanced imaging technologies and reinforce the company’s competitive position in nuclear medicine. However, the program’s financial contribution will depend on the pace of commercialization, regulatory clearances and eventual customer demand for StarGuide GX.
GEHC Stock Trend Following the News
Following the announcement on Oct. 20, GEHC stock has traded flat till yesterday’s closing. Year to date, shares of the company have lost 15.9% compared with the industry’s 20% decline and the S&P 500’s 12.7% rise.
The global clinical evaluation program could support GEHC’s long-term growth by strengthening the clinical evidence behind its advanced molecular imaging portfolio and expanding the potential applications of the StarGuide GX platform. Feedback from leading healthcare institutions may help refine the system’s quantitative imaging capabilities, improve clinical workflows and support the development of next-generation nuclear medicine solutions. These advances could enhance GEHC’s competitive positioning in theranostics and precision oncology, where demand for technologies that help guide treatment decisions and monitor therapeutic response is growing.
GEHC currently has a market capitalization of $108.02 billion.
Image Source: Zacks Investment Research
More on the News
GEHC StarGuide GX is a next-generation digital 4D single-photon emission computed tomography/computed tomography (SPECT/CT) system designed to advance quantitative and dynamic imaging in nuclear medicine. The platform uses dual-sided cadmium zinc telluride (dsCZT) detector technology to support high-sensitivity, high-resolution imaging and quantitative assessment. Its detector configuration allows the detectors to move closer to the patient during imaging, while the patented dual-collimator design is intended to eliminate manual external collimator exchanges and streamline workflows. These features are designed to support imaging efficiency while improving the precision of nuclear medicine assessments.
The system is engineered to accommodate radionuclides across a broad energy range, with research evaluations potentially extending to radionuclides associated with emerging alpha-emitter applications, including Actinium-225. This could help expand its potential role in theranostics, which combines diagnostic imaging with targeted treatment. In addition, NVIDIA RTX accelerated computing supports image reconstruction, while the Low-Medium Energy collimator is designed to deliver up to 2.67 times system volume sensitivity. Together, these capabilities could help clinicians obtain more detailed imaging data and support the evolving requirements of personalized medicine and advanced oncology care.
The five participating institutions will evaluate the platform according to their clinical and research priorities. Hadassah Medical Center will assess its advanced quantitative capabilities following a recent field upgrade, while Mayo Clinic will focus on quantitative and dynamic imaging applications. Oncopole Claudius Regaud in France will evaluate the system in routine oncology imaging and clinical research, Peking University First Hospital will explore novel tracer research and preclinical applications, and Rambam Health Care Campus will assess imaging workflows across a broad range of nuclear medicine applications and tracers.
The program builds on GEHC’s collaboration with University Hospital Essen in Germany, which opened a nuclear medicine center in June 2026 featuring the first installation of StarGuide GX SPECT/CT. The participating institutions have collectively conducted more than 1,000 patient scans.
StarGuide GX received CE Mark in November 2025 and is available for sale in select European Union member states. However, FDA 510(k) clearance remains pending, and the system is not currently available for sale in the United States.
Industry Prospects Favoring the Market
According to data provided by Mordor Intelligence, the radiopharmaceutical theranostics market size is expected to grow from $2.66 billion in 2026 to $4.46 billion by 2031 at 10.89% CAGR.
The radiopharmaceutical theranostics market is driven by rising cancer incidence, growing adoption of targeted radioligand therapies and increasing demand for precision oncology. Advances in radiopharmaceuticals, expanding clinical applications, favorable regulatory developments and investments in isotope production and nuclear medicine infrastructure are expected to support long-term market growth.
Other News
GEHC recently announced that the MINItrace Magni cyclotron has received CE Mark certification, advancing its efforts to expand local production of radioisotopes used in positron emission tomography (“PET”) imaging. The company also expanded the PETtrace Solid Target Platform to support Copper-64 production, broadening its capabilities beyond Gallium-68 and Zirconium-89.
GEHC’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.